期刊
NATURE COMMUNICATIONS
卷 8, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-017-01867-9
关键词
-
资金
- NCI [F31 CA192787, F30 CA200272, R01 CA175061, R01 CA208514, P01 CA154778]
- ACS [122709-PF-13-084-01-L1B]
- MUSC start-up funds
CD8(+) T lymphocytes mediate potent immune responses against tumor, but the role of human CD4(+) T cell subsets in cancer immunotherapy remains ill-defined. Herein, we exhibit that CD26 identifies three T helper subsets with distinct immunological properties in both healthy individuals and cancer patients. Although CD26(neg) T cells possess a regulatory phenotype, CD26(int) T cells are mainly naive and CD26(high) T cells appear terminally differentiated and exhausted. Paradoxically, CD26(high) T cells persist in and regress multiple solid tumors following adoptive cell transfer. Further analysis revealed that CD26(high) cells have a rich chemokine receptor profile (including CCR2 and CCR5), profound cytotoxicity (Granzyme B and CD107A), resistance to apoptosis (c-KIT and Bcl2), and enhanced stemness (beta-catenin and Lef1). These properties license CD26(high) T cells with a natural capacity to traffic to, regress and survive in solid tumors. Collectively, these findings identify CD4(+) T cell subsets with properties critical for improving cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据